Steven E Nissen MD

Preventive Cardiology

Professor of Medicine, Cleveland Cl College of Medicine/Case West Res Chief Academic Officer - Heart, Vascular, and Thoracic Institute, Cleveland Clinic

Join to view full profile

9500 Euclid AveCleveland, OH 44195
Phone+1 800-223-2273
Fax+1 216-445-6855

Dr. Nissen is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nissen's full profile Already have an account?

Summary

Dr. Steven Nissen is a cardiologist based in Cleveland, OH, specializing in preventive cardiology. He completed his medical education at the University of Michigan Medical School and a fellowship in cardiovascular disease at the University of Kentucky College of Medicine. Dr. Nissen has extensive experience in preventive cardiology, hypertension, coronary artery disease, and clinical trials. He has contributed to several high impact publications, including articles in the New England Journal of Medicine and the Journal of the American Medical Association (JAMA). His involvement in clinical trials covers areas such as the progression and regression of coronary atherosclerosis, diabetes and heart disease, . Throughout his career, Dr. Nissen has received several honors, including recognition as one of America's Top Doctors by Castle Connolly and named by Time Magazine as one of the 100 most influential people in the world.

Education & Training

University of Kentucky College of MedicineFellowship, Cardiovascular Disease, 1981 - 1983
University of Michigan Medical SchoolClass of 1978

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 1992 - 2028
CA State Medical License 1980 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016
CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2016
America's Top Doctors Castle Connolly, 2004-2014

Clinical Trials

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia Start of enrollment: 2014 Oct 30
COMPLETED
PHASE3
The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis
TERMINATED
PHASE4
Supplements, Placebo, or Rosuvastatin Study Start of enrollment: 2021 Apr 23
COMPLETED
PHASE2

Publications & Presentations

PubMed

Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial.
Marc P Bonaca, Mario Enrico Canonico, Na Li, William J Sasiela, Steven E Nissen
Circulation. 2026-08-18
In Reply: The intersection of CHIP and HIV: Implications for cardiovascular risk stratification.
Ohad Oren, Abhay Singh, Hetty E Carraway, Luke J Laffin, Steven E Nissen
Cleveland Clinic Journal of Medicine. 2026-08-03
Novel risk model for predicting incident atrial fibrillation in patients taking ω-3 fatty acid: sub-analysis of the STRENGTH randomized trial.
Tom Kai Ming Wang, Stephen J Nicholls, Clement Tan, Becky Yi-Wen Liao, Kathy Wolski
American Journal of Preventive Cardiology. 2026-08-01

Journal Articles

Coronary Revascularization Strategies
Steven E Nissen, Faisal G Bakaeen, JAMA
Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular Disease
Steven E Nissen, JAMA Cardiology
Original Investigation Effect of Evolocumab on Coronary Plaque Composition
Steven E Nissen, Ransi Somaratne, Rishi Puri, Christie M Ballantyne, ScienceDirect

Lectures

ADCY9 Genetic Variants and Cardiovascular Outcomes with Evacetrapib in Patients with High-Risk Vascular Disease
Inova Health System, Mclean, Virginia - 4/26/2013
Debate: The LDL Limbo. How Low Should You Go?
ENDO 2018: 100th Endocrine Society Annual Meeting - Chicago, Illinios - 03/17/2018

Authored Content

Coronary Revascularization StrategiesJuly 2020
Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseJuly 2020
Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseJuly 2020

Press Mentions

The Future of Health—From Head to ToeJune 14th, 2026
First Human Trial of a CRISPR-Based Treatment Significantly Lowered Cholesterol and TriglyceridesNovember 17th, 2025
$CRISPR-Cas9 Gene Editing for Refractory Dyslipidemia Shows Safety and Preliminary Efficacy$
CRISPR-Cas9 Gene Editing for Refractory Dyslipidemia Shows Safety and Preliminary EfficacyNovember 10th, 2025